Company intelligence / Profile preview
Gnubiotics Sciences SA
Lausanne (Epalinges), Vaud, Switzerlandgnubiotics.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Gnubiotics has demonstrated biological proof of concept for their glycopeptides in activating 4 major biological systems. Their lead candidate GNU101 is a promising glycopeptide for immunotherapy. Their products have shown efficacy in microbiome modulation and metabolic syndrome applications.
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyInfectious Diseases
- Modalities
- GlycopeptidesO-linked glycopeptidesHuman Milk Oligosaccharide (HMO) mimics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
ADM (Archer Daniels Midland)
Beyond the preview
Go deeper on Gnubiotics Sciences SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gnubiotics Sciences SA.